Acusphere, Inc. (OTCPK: ACUS)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Acusphere, Inc. (OTCPK: ACUS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.00 and employs 50 people.
trading between 0.00 and 0.00.
Tweenvest scores Acusphere, Inc. across four factors: value 50/100. Its strongest factor is value.
ACUS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.00
- Revenue (TTM)
- $2.68M
- P/E
- —
- EPS
- -14.64
- Dividend yield
- —
- Beta (5Y)
- -0.45
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 4.95M
- Employees
- 50
- Next earnings
- —
About Acusphere, Inc.
Acusphere, Inc. is a pharmaceutical firm specializing in the creation and market launch of cardiovascular treatments. Its flagship product is Imagify (perflubutane polymer microspheres), a cardiovascular medication designed to assess myocardial perfusion and aid in the diagnosis of coronary artery disease. This drug is administered as an injectable suspension. Initially established as Polymers For Medicine, Inc., the organization rebranded as Acusphere, Inc. in March 2004. Founded in 1993, the company maintains its headquarters in Watertown, Massachusetts.
- ISIN
- US00511R8549
- Founded
- 1993
- Listed since
- Oct 8, 2003
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.